Levofolinic acid

Folate Analog — VARIOUS

Key facts

Levofolinic acid is an ofp drug in the Folate Analog class catalogued in DrugCentral. It was first approved by the FDA in 2008. Recorded indications include Adjunct to Fluorouracil Treatment of Colorectal Cancer, Bone Marrow Suppression due to Folic Acid Antagonism, Folic acid deficiency and Malignant tumor of stomach.

• Approval status: ofp (first approved 2008 by the FDA).
• Drug class: Folate Analog.
• Indications: Adjunct to Fluorouracil Treatment of Colorectal Cancer, Bone Marrow Suppression due to Folic Acid Antagonism, Folic acid deficiency, Malignant tumor of stomach and Megaloblastic anemia and others.
• ATC code: V03AF04 (Detoxifying agents for antineoplastic treatment).
• Molecular formula: C20H23N7O7; molecular weight 473.45 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (11)

• Adjunct to Fluorouracil Treatment of Colorectal Cancer
• Bone Marrow Suppression due to Folic Acid Antagonism
• Folic acid deficiency
• Malignant tumor of stomach
• Megaloblastic anemia
• Methotrexate Toxicity
• Pyrimethamine Toxicity
• Small intestine cancer
• Sulfadiazine Toxicity
• Trimethoprim Toxicity
• Trimetrexate Toxicity

Mechanism & targets

• Established pharmacologic class: Folate Analog

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2018-09-21	PMDA	—	Pfizer Japan Inc.
2008-03-07	FDA	—	SPECTRUM PHARMS	Yes

ATC classification

ATC code	Therapeutic hierarchy
V03AF04	VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Detoxifying agents for antineoplastic treatment
V03AF10	VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Detoxifying agents for antineoplastic treatment

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Dermatitis acneiform	762.0
Neutrophil count decreased	649.0
Paronychia	587.7
Neutropenia	474.6
Interstitial lung disease	425.9
Neuropathy peripheral	405.9
Peripheral sensory neuropathy	349.1
Decreased appetite	346.0
Hyperammonaemia	260.2
Hypomagnesaemia	222.4
Diarrhoea	214.6
Stomatitis	194.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Levofolinic acid is on its molecule page.

• Molecular formula: C₂₀H₂₃N₇O₇
• Molecular weight: 473.45 g/mol
• CAS number: 80433-71-2
• InChIKey: VVIAGPKUTFNRDU-STQMWFEESA-N
• PubChem CID: 135398559

NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Levofolinic acid used for?

DrugCentral lists the following indications for Levofolinic acid: Adjunct to Fluorouracil Treatment of Colorectal Cancer, Bone Marrow Suppression due to Folic Acid Antagonism, Folic acid deficiency, Malignant tumor of stomach, Megaloblastic anemia, Methotrexate Toxicity, Pyrimethamine Toxicity and Small intestine cancer and others.

When was Levofolinic acid first approved?

Levofolinic acid was first approved by the FDA in 2008.

What drug class does Levofolinic acid belong to?

Levofolinic acid is in the Folate Analog class.

What is the chemical formula of Levofolinic acid?

Levofolinic acid has the molecular formula C20H23N7O7 and a molecular weight of 473.45 g/mol.

Sources

• DrugCentral drug card 4384 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1908361 — compound record and bioactivity
• PubChem CID 135398559 — chemical identifiers
• DrugBank DB11596 — drug record
• FDA UNII WA16A5Y52X — substance identity
• DailyMed: FDA labels for Levofolinic acid — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.